Remedy Cell

Remedy Cell is a clinical-stage biopharmaceutical company advancing a novel class of cell-derived, cell-free therapies designed to address significant unmet needs in fibrotic diseases. The company’s lead program, RC-0315, is currently in a Phase 1b clinical trial for Idiopathic Pulmonary Fibrosis (IPF), a severe and underserved condition with limited therapeutic options. Backed by an experienced leadership team, world-class scientists, and globally recognized clinical and industry experts, Remedy Cell is positioned to deliver transformative therapies with the potential to redefine the standard of care across pulmonary fibrosis and broader fibrotic indications.